Talphera (TLPH) EBITDA Margin (2011 - 2025)

Talphera (TLPH) posted quarterly EBITDA Margin of 342200.0% for Q3 2025, down 3068.52% quarter-over-quarter from 10800.0% in Q1 2025.

Talphera (TLPH) EBITDA Margin (2011 - 2025) Analysis & Trends

Talphera's EBITDA Margin history runs 14 years deep, the most recent figure standing at 342200.0% for Q3 2025.

In Q3 2025, EBITDA Margin changed N/A year-over-year to 342200.0%; the TTM figure through Mar 2026 stood at 1451600.0% (down 140000370.0% YoY), while the FY2025 annual figure was 48157.14%, changed N/A from the prior year.
EBITDA Margin for Q3 2025 stood at 342200.0%, down from 10800.0% in the prior quarter.
The five-year high for EBITDA Margin was 41.92% in Q1 2023, with the low at 408750.0% in Q4 2021.
The 4-year median for EBITDA Margin is 2035.07% (2022), against an average of 70391.43%.
Peak annual rise in EBITDA Margin reached 231666 bps in 2021, while the deepest fall reached 40749743 bps in 2021.
Talphera's EBITDA Margin stood at 408750.0% in 2021, then surged by 100 bps to 2035.07% in 2022, then advanced by 25 bps to 1524.2% in 2023, then sank by 22351 bps to 342200.0% in 2025.
Business Quant data shows TLPH's EBITDA Margin at 342200.0% in Q3 2025, 10800.0% in Q1 2025, and 1524.2% in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Haleon	43.91 Bn	42.95 Bn	-	-
2	Teva Pharmaceutical Industries	43.07 Bn	39.42 Bn	2.15 Bn	-5.58%
3	Zoetis	31.54 Bn	29.86 Bn	1.05 Bn	33.91%
4	Takeda Pharmaceutical	28.61 Bn	22.81 Bn	5.10 Bn	16.51%
5	United Therapeutics	22.19 Bn	19.53 Bn	683.80 Mn	42.23%
6	Viatris	18.68 Bn	17.79 Bn	1.46 Bn	0.17%
7	Neurocrine Biosciences	15.50 Bn	15.11 Bn	935.80 Mn	15.80%
8	Elanco Animal Health	11.76 Bn	11.23 Bn	798.00 Mn	18.13%
9	Dr Reddys Laboratories	10.12 Bn	9.96 Bn	-	-
10	Talphera	89.95 Mn	89.95 Mn	-	-

Download Data